Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01730170 · ClinicalTrials.gov registry record
Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD)
A clinical trial of Pregnancy and Epilepsy, sponsored by Stanford University.
- Completed
- Registry status
- 565
- Enrollment target
- 20
- Study locations
NCT01730170 is a study of Pregnancy and Epilepsy that has completed, run by Stanford University. The registered enrollment target is 565 participants, below the 870-participant average among 191 other Pregnancy trials with a reported enrollment target (35% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT01730170, a study of Pregnancy and Epilepsy, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 565 participants
- Enrollment target
- 20
- Study locations
Study Summary
Epilepsy is one of the most common neurological disorders affecting women of childbearing age. Poor pregnancy outcomes are increased in these women and their children. The proposed studies will increase our knowledge on multiple levels to improve care and reduce adverse outcomes in these mothers and children. An overall goal of this study is to establish the relationship between antiepileptic drug exposure and outcomes in the mother and child as well as describe and explain the variability in antiepileptic drug exposure and response.
Study Locations (20)
New York
- North Shore Jewish Medical Center - Manhasset
- New York University School of Medicine - New York
- Columbia University Medical Center/NY Presbyterian Hospital - New York
California
- Keck Hospital of the University of Southern California - Los Angeles
- Stanford University - Stanford
Georgia
- Emory University School of Medicine - Atlanta
- Medical College of Georgia at Georgia Regents University - Augusta
Pennsylvania
- Geisinger Medical Center - Danville
- University of Pittsburgh Medical Center - Pittsburgh
Alabama
- University of Alabama Birmingham Hospital- UAB - Birmingham
Arizona
- University of Arizona - University Medical Center - Tucson
Florida
- University of Miami Hospital - University of Miami School of Medicine - Miami
Illinois
- Northwestern Memorial Hospital-Northwestern University Feinberg School of Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 565 participants |
| Start Date | 2013-01 |
| Est. Completion | 2022-12-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01730170
The ClinicalTrials.gov registry entry for NCT01730170 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 565 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 870-participant average among 191 other Pregnancy trials with a reported enrollment target (35% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pregnancy appearing as the primary indexed condition, and to 0 interventions.
NCT01730170 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT01730170 about?
NCT01730170 is a clinical study titled "Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD)". Epilepsy is one of the most common neurological disorders affecting women of childbearing age. Poor pregnancy outcomes are increased in these women and their children. The proposed studies will increase our knowledge on multiple levels to improve care and reduce adverse outcomes in these mothers and...
What is the current status of trial NCT01730170?
This trial is currently completed. The enrollment target is 565 participants. The study started on 2013-01. Estimated completion is 2022-12-12.
What conditions does trial NCT01730170 study?
This clinical trial studies the following conditions: Pregnancy, Epilepsy.
Who is sponsoring clinical trial NCT01730170?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01730170 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pregnancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes
RECRUITING · NA
-
Healthy Start: Exploring the Fuel-mediated Programming of Neonatal Growth
RECRUITING
-
Cocooned Moms Study
RECRUITING · NA
-
Retinal Vascular Changes During Pregnancy
RECRUITING
-
CGM for Management of Type 2 Diabetes in Pregnancy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.